Oslo, Norway, 27 August 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its first half 2026 results.
Presentation:
Oncoinvent's management will give an online presentation to investors, analysts and the press at 10:00am CEST today. It will be possible to submit questions during the presentation.
· Presenters: CEO Oystein Soug, CFO Ramzi Amri · Time: 10:00am CEST · Webcast link: https://qcnl.tv/p/FlGvKEVec2WWcnTYYHBK4g
A recording of the webcast will be made available on www.oncoinvent.com after the live sending.
Highlights:
· Achieved 50% recruitment milestone in Phase 2 ovarian cancer study of
Radspherin[®]
· Added four new clinical sites to Oncoinvent's Phase 2 trial · Presented positive 24-month follow-up data from Phase 1 ovarian cancer trial of Radspherin[®] at 27th Congress of the European Society of Gynaecological Oncology (ESGO) 2026 · Appointed Dr Ramzi Amri as Chief Financial Officer (CFO) · Secured new patent expanding protection for Radspherin[®]
Post-period highlights:
· Announced publication of normal tissue dosimetry results in Journal of
Nuclear Medicine
· Announced abstracts accepted at two major scientific conferences:
· European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (23-27 October) · European Association of Nuclear Medicine (EANM) Annual Congress 2026 in Vienna, Austria (17-21 October)
Oystein Soug, CEO, commented: "We entered the year with a clear focus on accelerating patient recruitment, and I am pleased to say that these efforts are delivering tangible results. Recruitment momentum accelerated significantly during the first half of the year, reinforcing our confidence in the potential of Radspherin[®] to address a significant unmet medical need in ovarian cancer."
Key financial figures
AMOUNTS IN 1 000 NOK 1H 2026 1H 2025 FY2025
Total operating revenue 8 203 11 960 28 069 Total operating expenses (77 195) (63 978) (186 399) Operating profit (-loss) (68 992) (52 018) (158 330) Cash 108 839 77 412 179 670 Earnings per share (EPS) (15.20) (54.01) (125.13) # Shares 4 478 412 962 544 1 239 249 Employees (FTEs) 42 36 44
The interim financial information has not been subject to audit
Reporting material:
· Oncoinvent 1H26
report (https://mb.cision.com/Public/15728/4388369/bdad65ca09ac9f58.pdf)
· Oncoinvent 1H26
presentation (https://mb.cision.com/Public/15728/4388369/94411c85f34ede0a.pdf)
The reporting material are also available in the Investor Relations section of the Company's website at www.oncoinvent.com.
Oncoinvent reports its financial results on a half-yearly basis, complemented by quarterly business updates to keep stakeholders informed and ensure ongoing transparency.
For further information, please contact:
Oystein Soug, Chief Executive Officer Email: IR@oncoinvent.com (soug@oncoinvent.com)
This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5 -12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent's product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care.
The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent's plans, estimates, or expectations will be achieved. These forward -looking statements represent Oncoinvent's expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward -looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.